Novo Nordisk® logo
NovoCare® Savings | Coverage | Support NovoCare® Savings | Coverage | Support
Novo Nordisk® logo

NovoCare® SMS Terms of Use for Diabetes

Last Updated January 10, 2025

  1. Agreement Generally: Acceptance. These “Terms of Use” (the “Agreement” or “Terms of Use”) are between you and the Novo Nordisk’s NovoCare® SMS for Diabetes (“NovoCare® SMS Diabetes,” “we,” “us,” or “our”). “You” means you personally. This Agreement sets forth the terms and conditions upon which we make available the NovoCare® SMS Diabetes contents to you.

    Please note these Terms of Use govern only the NovoCare® SMS Diabetes. These Terms of Use are not for any other service, program, or website. By opting to receive the NovoCare® SMS Diabetes, you are agreeing to these Terms of Use. By receiving the NovoCare® SMS Diabetes, you affirm that you are a US resident and 18 years of age or older.
  2. For more information about data use and collection, please read the most recent version of Novo Nordisk’s Privacy Notice https://www.novonordisk-us.com/privacy-notice.html.

    PLEASE READ THESE TERMS OF USE CAREFULLY BEFORE AGREEING TO RECEIVE THE NOVOCARE®     SMS DIABETES.

    IF YOU DO NOT AGREE TO THESE TERMS OF USE, YOU CANNOT RECEIVE THE NOVOCARE®     SMS DIABETES.
  1. Eligibility. To participate in the NovoCare® SMS Diabetes Program, you must be a citizen and/or resident of the United States and 18 years of age or older (or, if the patient is under 18, then a parent, guardian, or legal representative must be 18 years of age or older). Novo Nordisk reserves the right to require you to prove that you meet this eligibility criteria. THE NOVOCARE® SMS DIABETES IS NOT INTENDED FOR HEALTH CARE PROFESSIONALS AND/OR INDIVIDUALS WHO ARE UNDER 18 YEARS OF AGE.
  2. Modifications to Terms of Use. You agree that we may modify these Terms of Use and that such modifications shall become effective immediately upon posting of the modified Terms of Use to our website or otherwise notifying you of an update through the NovoCare® SMS Diabetes. If you do not accept the modifications, you must cease using the NovoCare® SMS Diabetes. The Terms of Use contain the date of posting at the top of the first page.
  3. Permission to Use NovoCare® SMS Diabetes; Limitations on Use of the NovoCare® SMS Diabetes. Subject to your acceptance and while you remain in compliance with the Terms of Use, we grant you a limited, revocable, non-exclusive, non-transferable license to use the NovoCare® SMS Diabetes solely and exclusively for your own use and not for any other purpose. All other uses of the NovoCare® SMS Diabetes are prohibited.
  4. Communication Options. To opt in to the NovoCare® SMS Diabetes, you must opt in (either through the NovoCare® Patient Authorization Form or verbally with the NovoCare® Call Center) to participate in the NovoCare® SMS Diabetes. You will then receive a text message where you will be required to text back YES to further opt in to start receiving these text messages. If you text YES, a confirmation text message will be sent to the phone number you used to text 407-707-6590. By choosing to enroll in the NovoCare® SMS Diabetes, you will receive program status updates only. However, specific words will trigger an automated response as noted below. We do not guarantee that the NovoCare® SMS Diabetes communications will be received and are not responsible for lost or misdirected communications.

    You can opt out of the NovoCare® SMS Diabetes at any time by sending a reply text stating STOP to 407-707-6590. You will receive a confirmation text message immediately upon replying STOP and will be fully opted out of the text message program at that point.

    PLEASE NOTE that opting out of the NovoCare® SMS Diabetes does not unsubscribe and/or opt you out of any future communications from Novo Nordisk or its partners that you may have previously signed up for separate and apart from the NovoCare® SMS Diabetes. Please follow instructions specific to those other, non-marketing communications to opt out. You may opt out of marketing communications with Novo Nordisk or its partners by clicking the “Unsubscribe” link within any email you receive from Novo Nordisk or its partners, by calling 1‑800‑727‑6500, clicking     here, or sending Novo Nordisk a letter containing your name, email address, and phone number to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536.

    For additional customer support for NovoCare® SMS Diabetes, you can call 1‑888‑809‑3942.
  1. Text Messaging. If you choose to enroll in the NovoCare® SMS Diabetes, the following terms apply:
    1. Text Message Frequency. The NovoCare® SMS Diabetes’s message frequency will vary. Please be aware that Novo Nordisk brands and services may have separate text messaging programs. The total number of text messages you receive from Novo Nordisk or its partners, therefore, may vary based on the number of Novo Nordisk text messaging programs for which you sign up to receive messages.
    2. Cost. You will not be charged any fee from Novo Nordisk or its partners in connection with the NovoCare® SMS Diabetes to receive automated text messages. However, Novo Nordisk encourages you to check with your mobile service provider to see what other message and data rates may apply, including any applicable roaming charges. Novo Nordisk is not responsible for any fees or charges from any carrier or service provider related to the NovoCare® SMS Diabetes communications.
    3. Supported Carriers. The following US carriers are supported:
      1. Major Carriers: AT&T, Verizon Wireless, Sprint, and T-Mobile USA.
      2. Minor Carriers: Aio Wireless, Alaska Communications Systems (ACS), Appalachian Wireless (EKN), Bluegrass Cellular, Boost Mobile, Carolina West Wireless, CellCom, Cellular One of East Central IL (ECIT), Cellular One of Northeast Arizona, Cellular One of Northeast Pennsylvania, Chariton Valley Cellular, Cricket, Coral Wireless (MobiPCS), Cross, C-Spire (CellSouth), Duet IP (Maximum Communications New Core Wireless), Element Mobile (Flat Wireless), Epic Touch (Elkhart Telephone), GCI, Golden State, Google Voice, Hawkeye (Chat Mobility), Hawkeye (NW Missouri), Illinois Valley Cellular, Inland Cellular, iWireless (Iowa Wireless), Keystone Wireless (Immix Wireless/PC Man), Metro PCS, Mosaic (Consolidated or CTC Telecom), MTA Communications, MTPCS (Cellular One Nation), Nex-Tech Wireless, Panhandle Communications, Peoples Wireless, Pine Cellular, Pioneer, RINA, Sagebrush Cellular (Nemont), SI Wireless/Mobile Nation, Simmetry (TMP Corporation), SouthernLinc, SRT Wireless, Thumb Cellular, Union Wireless, United Wireless, U.S. Cellular, Viaero Wireless, Virgin Mobile, and West Central (WCC or 5 Star Wireless).
    4. Your Mobile Telephone Number. You represent that you are the account holder or authorized user for the mobile telephone number you opt in to receive text messages for the NovoCare® SMS Diabetes.
    5. Access or Delivery to Mobile Network Is Not Guaranteed. Delivery of information and content to a mobile device is not guaranteed and may fail due to a variety of circumstances or conditions. Alerts sent via text message may not be delivered if the mobile phone is not in range of a transmission site, or if sufficient network capacity is not available at a particular time. Even within a coverage area, factors beyond the control of the wireless carrier may interfere with message delivery, including the customer's equipment, terrain, proximity to buildings, foliage, and weather. Novo Nordisk will not be held responsible for any delays in the receipt of any text messages as delivery is subject to effective transmission from your mobile service provider or network operator. You understand and acknowledge that network services, including but not limited to mobile network services, are outside of Novo Nordisk’s control. Note that there may be data or message fees imposed by your carrier or service provider if you choose to receive text messages from the NovoCare® SMS Diabetes.
  1. Privacy & Security. As noted above, to enroll in the NovoCare® SMS Diabetes, you must follow the enrollment process above. Novo Nordisk does not retain any information about you except in furtherance of transmitting the NovoCare® SMS Diabetes. Your phone number will not be shared with Novo Nordisk service providers. Novo Nordisk may use non-identifiable, engagement information for commercial insights and analytics as well as product improvements. For more information on how we collect and use your information, please read our full Privacy Notice https://www.novonordisk-us.com/privacy-notice.html.
  2. Content. All information available in or provided through the NovoCare® SMS Diabetes is collectively referred to in these Terms as the “Content.” The Content will include program status updates. The Content is provided for your personal, noncommercial use only. You may access, view, use, display, and download the Content, but you do not receive any ownership in or to the Content or any copies thereof. You may not sell, give, reproduce, create derivative works of, publicly display, or otherwise distribute the Content to anyone other than your physician(s) or caregiver(s). All rights not expressly granted herein are reserved. Novo Nordisk assumes no responsibility for the accuracy or appropriateness of any information provided to you through the NovoCare® SMS Diabetes.

    All rights not expressly granted herein are reserved. Novo Nordisk assumes no responsibility for the accuracy or appropriateness of any information provided by you through the NovoCare® SMS Diabetes.
  3. NOT MEDICAL ADVICE. The NovoCare® SMS Diabetes is only informational in nature and is not meant to be medical in nature. OUR CONTENT AND COMMUNICATIONS ARE NOT INTENDED TO BE A REPLACEMENT OR SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE. THE CONTENT AND COMMUNICATIONS DO NOT CONSTITUTE MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT. You understand that Novo Nordisk does not endorse any particular physician or health care professional for the treatment of any specific medical condition. You further understand that the NovoCare® SMS Diabetes is not a means to communicate product issues or negative side effects to Novo Nordisk. You are encouraged to report negative side effects of prescription drugs to the FDA at www.fda.gov/medwatch or by phone at 1‑800‑FDA‑1088. Novo Nordisk does not monitor or record the NovoCare® SMS Diabetes. For additional information about NovoCare®, please call 1‑833‑885‑3146.
  1. Prohibited Activity. You will not: (a) access or attempt to access the NovoCare® SMS Diabetes or any part thereof that you are not authorized to access or through any means that you are not authorized to use; (b) disrupt or interfere with the security of, or otherwise cause harm to the NovoCare® SMS Diabetes, systems, resources, accounts, passwords, servers or networks connected to or accessible through the NovoCare® SMS Diabetes or any affiliated or linked websites or access or use the NovoCare® SMS Diabetes in any manner that could damage, disable, overburden, or impair any server or network used by us in connection with the NovoCare® SMS Diabetes; (c) use the NovoCare® SMS Diabetes in any manner that infringes upon or violates any intellectual property rights or other rights or interest of any party or otherwise constitutes pornography, defamation, harassment, bullying, predatory behavior, false and deceptive advertising, or hate speech; (d) submit any software, programs, or files via the NovoCare® SMS Diabetes that are harmful or disruptive of another’s equipment, software, or other property, including any corrupted files, time bombs, Trojan Horses, viruses, and worms; (e) disrupt, interfere with, or inhibit any other user from using and enjoying the NovoCare® SMS Diabetes; (f) violate any applicable laws or regulations related to the access to or use of the NovoCare® SMS Diabetes, and/or engage in any activity prohibited by the Terms of Use; (g) compile, use, download, or otherwise copy any materials available on the NovoCare® SMS Diabetes (except as expressly permitted), or transmit, provide, or otherwise distribute (whether or not for a fee) such materials to any third party; (h) use, or allow anyone else to use, any robot, spider, or other such programmatic or automatic device, including but not limited to automated dial-in or inquiry devices, to obtain information from the Site or otherwise monitor or copy any portion of the NovoCare® SMS Diabetes ram; (i) frame, mirror, or use framing techniques on any part of the NovoCare® SMS Diabetes without our express prior written consent; (j) make any use of, or allow anyone else to make any use of, data extraction, scraping, mining, or other data gathering tools, or create a database by systematically downloading or storing the NovoCare® SMS Diabetes, or any portion thereof, or otherwise scrape, collect, store, or use the NovoCare® SMS Diabetes except pursuant to the limited license granted by the Terms of Use; (k) modify, adapt, translate, reverse engineer, decompile, or disassemble any portion of the NovoCare® SMS Diabetes; or (l) remove any copyright, trademark, or other proprietary rights notice from the NovoCare® SMS Diabetes. These examples of prohibited conduct are illustrative and are not exhaustive.

    TO THE MAXIMUM EXTENT AUTHORIZED BY LAW, WE RESERVE THE RIGHT, BUT DISCLAIM ANY OBLIGATION WHATSOEVER, TO MONITOR OUR SITE AND YOUR COMPLIANCE WITH THIS SECTION AND WITH THE TERMS OF USE AS A WHOLE.
  2. Termination of NovoCare® SMS Diabetes. Novo Nordisk may suspend or terminate your use of the NovoCare® SMS Diabetes if Novo Nordisk believes you are in breach of these Terms of Use. Your receipt of NovoCare® SMS Diabetes communications is also subject to termination in the event that your telephone or network service terminates or lapses. Novo Nordisk reserves the right to modify or discontinue, temporarily or permanently, all or any part of the NovoCare® SMS Diabetes with or without notice. You assume sole responsibility for the proper use and scheduling of any medications, treatments, and procedures related to your health care and disease management.
  3. Assignment. You may not assign any of your rights or obligations hereunder, whether by operation of law or otherwise, without our prior written consent. Notwithstanding the foregoing, we may freely assign the Terms of Use, and the rights and obligations therein, without your consent, including but not limited to, in connection with a merger, acquisition, corporate reorganization, or sale of all or substantially all of our assets. Subject to the foregoing, the Terms of Use shall bind and inure to the benefit of the parties, their respective successors and permitted assigns.
  4. Entire Agreement. This Agreement, including the documents incorporated herein by reference, is the entire understanding and agreement between the NovoCare® SMS Diabetes and you with respect to the subject matter hereof.
  5. Miscellaneous. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision. In the event that any provision of this Agreement is found to be invalid or unenforceable, this Agreement shall be construed in accordance with its terms as if the invalid or unenforceable provision was not contained therein. No delay or failure by the NovoCare® SMS Diabetes to enforce any provision of this Agreement shall be a waiver of any of our rights under this Agreement.

    Terms are subject to change at any time.